Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study

Abstract

BackgroundDifferent pharmaceutical forms of oral tacrolimus allow tailored administration. The granular formulation facilitates accurate dose adjustment of tacrolimus according to patient characteristics, such as weight, or potential concomitant drug interactions. Currently, there are no data describing the use of tacrolimus granules in transplant recipients in France.Material/MethodsOPTIMOD was a 6-month prospective, observational multicenter study that aimed to describe patient characteristics and conditions of use of tacrolimus granules. The 25 participating centers enrolled patients at time of tacrolimus granules initiation and were to collect patient and treatment data at initiation and after 6 months of follow-up. All analyses were descriptive.ResultsOf 61 patients included, 55.7% were children (mainly kidney graft recipients) and 44.3% were adults (mostly lung graft recipients). Overall, 24.6% of patients (all children) initiated tacrolimus granules immediately post-transplant; the remaining 75.4% converted to tacrolimus granules from ciclosporin or immediate-release tacrolimus hard capsules. The main reasons for initiating tacrolimus granules, irrespective of whether first- or second-line therapy, were to offset potential drug–drug interactions in adults by adjusting dose, and to adapt to the particular needs of children as patients. Most patients (78.7%) underwent ≥1 dose modification during follow-up. Eleven rejection episodes occurred during follow-up, of which none led to graft loss. The adverse-event profile of the tacrolimus granules was similar to that of other tacrolimus formulations and 7 treatment-related adverse events were recorded.ConclusionsResults suggest that tacrolimus granules are well tolerated and effective in preventing transplant rejection when administered in routine practice in France.

Improvement in Medication Adherence Using TV Programmes as Reminders

“…These have been associated with medication non-adherence (Carpenter et al, 2020). Studies have reported taking medicine later 4.8% (Ma et al, 2019) is associated with medication non adherence (Garaix et al, 2018). While many patients consciously miss their medication (Sharkness & Snow, 1992;Webb et al, 2001).…”

The Moderating Effect of Demographics on Patient Adherence and Beliefs

“…Ensuring medication regime timing helps in recovery (Harris, Fry, & Fitzpatrick, 2019) but deferring from the scheduled time of medication is common among patients (Sharkness & Snow, 1992;Webb, Horne, & Pinching, 2001). This behaviour of patients is positively associated with non-adherence (Garaix, Stern, Lamy, Dubel, & Kamar, 2018). Approximately 50% of the patients suffering from hypothyroid in Nepal deferred from their scheduled time of medication.…”